• 1
    Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715720.
  • 2
    Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anaesthesiologist. Anaesthesiology 2002; 97: 215252.
  • 3
    Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997; 112: 676692.
  • 4
    Diegeler A, Doll N, Rauch T, Haberer D, Walther T, Falk V, Gummert J, Autschbach R, Mohr FW. Humoral immune response during coronary artery bypass grafting: a comparison of limited approach, ‘Off-Pump’ technique, and conventional cardiopulmonary bypass. Circulation 2000; 102: III95100.
  • 5
    Ranucci M, Mazzucco A, Pessotto R, Grillone G, Casati V, Porreca L, Maugeri R, Meli M, Magagna P, Cirri S, Giomarelli P, Lorusso R, de Jong A. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann Thorac Surg 1999; 67: 9941000.
  • 6
    Bennett-Guerrero E, Panah MH, Bodian CA, Methikalam BJ, Alfarone JR, DePerio M, Mythen MG. Automated detection of gastric luminal partial pressure of carbon dioxide during cardiovascular surgery using the Tonocap. Anaesthesiology 2000; 92: 3845.
  • 7
    Soeparwata R, Hartman AR, Frerichmann U, Stefano GB, Scheld HH, Bilfinger TV. Aprotinin diminishes inflammatory processes. Int J Cardiol 1996; 26: S5563.
  • 8
    Dingchao H, Zhiduan Q, Liye H, Xiaodong F. The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. Thorac Cardiovasc Surg 1994; 42: 276278.
  • 9
    Hindman BJ, Moore SA, Cutkomp J, Smith T, Ross-Barta SE, Dexter F, Brian JE Jr. Brain expression of inducible cyclooxygenase 2 messenger RNA in rats undergoing cardiopulmonary bypass. Anesthesiology 2001; 95: 13801388.
  • 10
    Erez E, Erman A, Snir E, Raanani E, Abramov D, Sulkes J, Boner G, Vidne BA. Thromboxane production in human lung during cardiopulmonary bypass: beneficial effect of aspirin? Ann Thorac Surg 1998; 65: 101106.
  • 11
    Jean YH, Wen ZH, Chang YC, Hsieh SP, Tang CC, Wang YH, Wong CS. Intra-articular injection of the cyclooxygenase-2 inhibitor parecoxib attenuates osteoarthritis progression in anterior cruciate ligament-transected knee in rats: role of excitatory amino acids. Osteoarthritis Cartilage 2007; 15: 638645.
  • 12
    Shafique T, Johnson RG, Dai HB, Weintraub RM, Sellke FW. Altered pulmonary microvascular reactivity after total cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993; 106: 479486.
  • 13
    Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008; 38: 165187.
  • 14
    Riest G, Peters J, Weiss M, Dreyer S, Klassen PD, Stegen B, Bello A, Eikermann M. Preventive effects of perioperative parecoxib on post-discectomy pain. Br J Anaesth 2008; 100: 256262.
  • 15
    Ng A, Smith G, Davidson AC. Analgesic effects of parecoxib following total abdominal hysterectomy. Br J Anaesth 2003; 90: 746749.
  • 16
    Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF. Task force for the redefinition of myocardial infarction. Eur Heart J 2007; 28: 25252538.
  • 17
    Metais C, Li J, Simons M, Sellke FW. Serotonin-induced coronary contraction increases after blood cardioplegia-reperfusion: role of COX-2 expression. Circulation 1999; 100: II328334.
  • 18
    Livelli FD, Johnson RA, McEnany MT, Sherman E, Newell J, Block PC, DeSanctis RW. Unexplained in-hospital fever following cardiac surgery: natural history, relationship to postpericardiotomy syndrome, and a prospective study of therapy with indomethacin versus placebo. Circulation 1978; 57: 968975.
  • 19
    Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996; 93: 48854890.
  • 20
    Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 20572072.
  • 21
    McBride WT, Armstrong MA, Crockard AD, McMurray TJ, Rea JM. Cytokine balance and immunosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits. B J Anaesth 1995; 75: 724733.
  • 22
    Wan S, DeSmet JM, Barvais L, Goldstein M, Vincent JL, LeClerc JL. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 112: 806811.
  • 23
    Hauser GJ, Ben-Ari J, Colvin MP, Dalton HJ, Hertzog JH, Bearb M, Hopkins RA, Walker SM. Interleukin-6 levels in serum and lung lavage fluid of children undergoing open heart surgery correlate with postoperative morbidity. Intensive Care Med 1998; 24: 481486.
  • 24
    Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS 1992; 307: 97101.
  • 25
    Hayward R, Nossuli TO, Scalia R, Lefer AM. Cardioprotective effect of interleukin-10 in murine myocardial ischemia-reperfusion. Eur J Pharmacol 1997; 334: 157163.
  • 26
    Journois D, Israel-Biet D, Pouard P, Rolland B, Silvester W, Vouhe P, Safran D. High volume, zero balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 1996; 85: 965976.
  • 27
    O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008; 223: 114131.
  • 28
    Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 698701.
  • 29
    Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with anti-inflammatory actions generated fromomega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J Exp Med 2000; 192: 11971204.
  • 30
    Yin H, Cheng L, Langenbach R, Ju C. Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology 2007; 45: 159169.
  • 31
    Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol 2005; 174: 50335039.
  • 32
    Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 10811091.
  • 33
    Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6: 11911197.
  • 34
    Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005; 174: 43454355.
  • 35
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15201528.
  • 36
    Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano DT. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 14811492.
  • 37
    Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 22802288.
  • 38
    Ganne S, Rao U, Gelb AW. To use or not to use: the dilemma of NSAIDs and craniotomy. Eur J Anaesthesiol 2009; 26: 625626.
  • 39
    Khalil MW, Chaterjee A, Macbryde G, Sarkar PK, Marks RRD. Single dose parecoxib significantly improves ventilatory function in early extubation coronary artery bypass surgery: a prospective randomized double blind placebo controlled trial. Br J Anaesth 2006; 96: 171178.
  • 40
    Marcus AJ, Broekman MJ, Pinsky DJ. COX inhibitors and thromboregulation. New Engl J Med 2002; 347: 10251026.
  • 41
    Borgdorff P, Tangelder GJ, Paulus WJ. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. J Am Coll Cardiol 2006; 48: 817823.
  • 42
    Oshima K, Takeyoshi I, Tsutsumi H, Mohara J, Ohki S, Koike N, Nameki T, Matsumoto K, Morishita Y. Inhibition of cyclooxygenase-2 improves cardiac function following long-term preservation. J Surg Res 2006; 135: 380384.